Group 1: OTC Business Development - In 2025, the company's OTC product sales revenue experienced a decline due to external environment, market factors, and internal reforms, but no severe negative impact was reported. The company aims to stabilize and optimize its marketing system and organizational structure for future growth [1] - In 2026, the company plans to enhance its brand marketing strategy focusing on "century-old brand," "authentic medicinal materials," and "intangible cultural heritage craftsmanship," while expanding into new regions, channels, and customer groups [1] Group 2: Prescription Drug Business - The prescription drug business is expected to develop steadily in 2025, focusing on cardiovascular, neurological, immunomodulatory, digestive, and gynecological fields [2] - The company is implementing a product incubation strategy for major and exclusive products, enhancing its marketing system, and building a flat sales team to improve competitiveness [2] - Sales of the product "An Gong Niu Huang Wan" have seen a decline, prompting the company to adjust its operational pace and reduce inventory to prepare for future sales recovery [2] Group 3: Stem Cell Clinical Progress - As of 2025, clinical trials for stem cell treatments have progressed, with 45 subjects enrolled for ischemic stroke treatment and 10 subjects for autoimmune pulmonary alveolar proteinosis [3] - The clinical trial for treating autism with bone marrow-derived mesenchymal stem cells was initiated on August 26, 2025, and is proceeding as planned [3] Group 4: Innovative Drug R&D - The company is developing innovative drugs, including the anticoagulant YB209 and the cyclic peptide antibiotic YB211, alongside stem cell projects [4] - By mid-2025, the YB209 project completed immunogenicity research and closed its clinical phase I, while YB211 has initiated clinical phase II trials with subject enrollment ongoing [5] Group 5: Acquisition of Jixianglong - In October 2025, the company acquired a 51.6667% stake in Jixianglong for 310 million RMB to enhance its pharmaceutical production, R&D, and business collaboration [6] - This acquisition aligns with national industrial policies and the company's strategic planning, aiming to enrich product offerings and improve overall competitiveness [6]

Core Insights - Tong Ren Tang Guo Yao achieved a revenue of HKD 1.612 billion, representing a year-on-year growth of 5.7%, and a net profit of HKD 529 million for the reporting period [2] Group 1: Business Performance - The company launched several new products, including the NMN anti-aging series and other traditional Chinese medicine products, enhancing its product matrix [3] - Revenue from the Hong Kong market reached HKD 1.07 billion, showing a significant year-on-year increase of 16.9% despite challenges in the retail sector [6] - The company expanded its retail presence in Hong Kong, increasing the number of retail terminals to 29, a net addition of 2 stores compared to the previous year [6] Group 2: Research and Development - Tong Ren Tang Guo Yao strengthened its R&D efforts, achieving significant results in product innovation and safety studies, including the approval of Danggui Blood Supplement Granules [3][4] - The company signed a cooperation agreement with Macau University of Science and Technology to enhance research collaboration and product registration [3] Group 3: Marketing and Brand Promotion - The company actively engaged in marketing activities, including the "Tong Ren Tang Day" and the "9th Tong Ren Care Against Stroke" series, to promote its brand and cultural heritage [5][7] - Tong Ren Tang Guo Yao emphasized its commitment to public welfare as a core aspect of its brand culture, conducting health-related activities in collaboration with local institutions [7] Group 4: Future Outlook - For 2025, the company aims to focus on "adjustment and recovery, cost reduction, and efficiency enhancement," implementing strategies to optimize management, products, investments, and finances [7]

Core Viewpoint - The traditional Chinese medicine (TCM) industry is at a new historical starting point, presenting new development opportunities for companies like Tong Ren Tang [1] Financial Performance - In 2024, Tong Ren Tang achieved revenue of HKD 1,611.6 million, a 5.7% increase from HKD 1,524.9 million in 2023, with a net profit of HKD 529.2 million [3] - The final dividend per share increased to HKD 0.35 from HKD 0.33 in 2023 [3] - The Hong Kong market contributed over 50% to the company's total revenue, with a 16.9% year-on-year growth in revenue to HKD 1,069.7 million [3] Operational Strategy - The company expanded its retail presence in Hong Kong by adding two new retail outlets, enhancing market coverage [3] - Tong Ren Tang maintains a stable gross profit margin and had a debt ratio of 2.9% with cash and cash equivalents of approximately HKD 1.82 billion [4] - The company has a history of active dividend policies, with cumulative dividends reaching HKD 3 billion, reflecting strong cash flow and profitability [4] Product Development and Innovation - Tong Ren Tang is focusing on product innovation and research, launching several new products in 2024, including anti-aging and herbal formulations [5] - The company has received multiple patents for its products, enhancing its competitive edge [6][7] International Expansion - The company is actively expanding its international presence, with a sales network covering major regions including Asia, Oceania, North America, and Europe [8] - Tong Ren Tang is registering key products in Southeast Asian countries and has established a presence in New Zealand, becoming the largest TCM chain in the region [8][9] Brand and Market Positioning - The company emphasizes balancing commercial and social value, engaging in community health initiatives and promoting TCM culture [10] - Tong Ren Tang has strengthened its brand influence through advertising and participation in global trade events, receiving multiple awards for its brand recognition [11][12] Industry Outlook - The TCM industry is benefiting from favorable policies and increasing public interest in health, positioning it as a promising sector in the pharmaceutical field [13] - The company aims to enhance retail efficiency, diversify its product matrix, and invest in core projects to capture more market share [13]

Core Insights - The company reported a revenue of HKD 1,611.6 million for the year ending December 31, 2024, representing a year-on-year growth of 5.7% [1] - The net profit for the same period was HKD 529.2 million, with a profit attributable to shareholders of HKD 500.3 million, resulting in an earnings per share of HKD 0.60 [1] - The board proposed a final dividend of HKD 0.35 per share [1] Hong Kong Market Performance - The company achieved revenue of HKD 1,069.7 million in the Hong Kong market, marking a year-on-year increase of 16.9% [2] - Despite challenges in the retail sector, the company successfully implemented a major product strategy and enhanced market promotion, leading to a recovery in retail revenue in the second half of the year [2] - The company added 2 new retail outlets in Hong Kong during the year [2] Overseas Market Expansion - The company generated revenue of HKD 402.6 million from overseas markets, with a total of 47 retail outlets [2] - The company is focused on promoting traditional Chinese medicine culture internationally and expanding its market presence [2] - Revenue from the domestic distribution business in mainland China was HKD 139.4 million, indicating a gradual recovery [2] Production and R&D Strengthening - The company enhanced its core business by focusing on production quality management and technological innovation [3] - The production facility in Tai Po, Hong Kong, holds multiple certifications, ensuring high-quality product manufacturing [3] - The company has developed a comprehensive quality control system covering all stages from project initiation to production [3] New Product Development - The company launched several new products, including anti-aging NMN series and various herbal formulations, expanding its product matrix [4] - The company received approval for the registration of Angelica Blood Supplement Granules, further diversifying its product offerings [4] - Collaborations with universities and research institutions are ongoing to promote scientific research and product development [4] Intellectual Property Strategy - The company has accumulated 75 authorized patents and filed 8 international PCT applications as of December 31, 2024 [5] - The focus on developing new health products aligns with market trends and consumer demands [5] - The company aims to strengthen its competitive edge through robust intellectual property development [5] Brand Promotion and Market Influence - The company has intensified brand promotion efforts to enhance its international market presence [6] - Key brand activities included "Tong Ren Tang Day" and "9th Tong Ren Care Stroke Prevention," aimed at showcasing the company's cultural heritage [6] - Participation in various exhibitions has helped the company demonstrate its international development and traditional medicine culture [6] Marketing Strategies - The company has leveraged various media platforms to promote its products and traditional Chinese medicine research [7] - Marketing efforts include seasonal health education campaigns and enhanced e-commerce strategies through partnerships with major online platforms [7] - The company received multiple awards, reinforcing its brand reputation and market position [7] Future Outlook - The company anticipates new growth opportunities in the traditional Chinese medicine sector driven by supportive national policies and rising market demand [9] - Strategic initiatives for 2025 include cost reduction, efficiency enhancement, and optimizing management and investment strategies [9] - The company aims to solidify its leading position in both domestic and international markets while contributing to the sustainable development of the traditional Chinese medicine industry [9]